UA110910C2 - Karboksamidni pyrazole derivatives as bruton tyrosine kinase inhibitors, pharmaceutical composition on the basis and method of treatment (options) - Google Patents

Karboksamidni pyrazole derivatives as bruton tyrosine kinase inhibitors, pharmaceutical composition on the basis and method of treatment (options)

Info

Publication number
UA110910C2
UA110910C2 UAA201504267A UAA201504267A UA110910C2 UA 110910 C2 UA110910 C2 UA 110910C2 UA A201504267 A UAA201504267 A UA A201504267A UA A201504267 A UAA201504267 A UA A201504267A UA 110910 C2 UA110910 C2 UA 110910C2
Authority
UA
Ukraine
Prior art keywords
treatment
tyrosine kinase
karboksamidni
options
basis
Prior art date
Application number
UAA201504267A
Other languages
Ukrainian (uk)
Inventor
Джон Роберт Спрінгер
Балекудру Девадас
Денні Джеймс Герленд
Маргарет Ланахан Грепперхаус
Сеунгіл Хан
Сюзан Лендіс Хокермен
Роберт Оуен Хьюс
Еддін Сайя
Марк Едвард Шнуте
Шон Радж Селнесс
Деніел Патрік Уолкер
Жао-Куі Ван
Лі Ксінг
Крістоф Вольфганг Запф
Мікеллє Анн Шмідт
Original Assignee
Пфайзер Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Інк. filed Critical Пфайзер Інк.
Priority claimed from PCT/IB2013/059846 external-priority patent/WO2014068527A1/en
Publication of UA110910C2 publication Critical patent/UA110910C2/en

Links

Abstract

Даний документ описує сполуки,що утворюють ковалентні зв'язки з тирозинкіназою Брутона (ТКБ). Описані способи отримання таких сполук. Також описані фармацевтичні композиції, що містять такі сполуки. Описані способи використання інгібіторів ТКБ, самих по собі або в комбінації з іншими терапевтичними агентами, для лікування аутоімунних захворювань або станів, гетероімунних захворювань або станів, раку, включаючи лімфому, і запальних захворювань або станів.This document describes compounds that form covalent bonds with Bruton's tyrosine kinase (TKB). Methods for preparing such compounds are described. Also disclosed are pharmaceutical compositions containing such compounds. Described are the uses of TKB inhibitors, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

UAA201504267A 2012-11-02 2013-01-11 Karboksamidni pyrazole derivatives as bruton tyrosine kinase inhibitors, pharmaceutical composition on the basis and method of treatment (options) UA110910C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261721920P 2012-11-02 2012-11-02
PCT/IB2013/059846 WO2014068527A1 (en) 2012-11-02 2013-11-01 Bruton's tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
UA110910C2 true UA110910C2 (en) 2016-02-25

Family

ID=55700669

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201504267A UA110910C2 (en) 2012-11-02 2013-01-11 Karboksamidni pyrazole derivatives as bruton tyrosine kinase inhibitors, pharmaceutical composition on the basis and method of treatment (options)

Country Status (2)

Country Link
MA (1) MA38056B1 (en)
UA (1) UA110910C2 (en)

Also Published As

Publication number Publication date
MA38056A1 (en) 2018-01-31
MA38056B1 (en) 2018-08-31

Similar Documents

Publication Publication Date Title
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
AU2018236800B2 (en) DNA-PK inhibitors
MX2020010412A (en) Inhibitors of bruton's tyrosine kinase.
NZ752526A (en) Pyrrolobenzodiazepine conjugates
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
MX2017015574A (en) Inhibitors of bruton's tyrosine kinase.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
NZ700928A (en) Dna-pk inhibitors
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
SG10201902429PA (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
JO3366B1 (en) Pyrazolyl Quinoxaline Kinase Inhibitors
MX2014000964A (en) Substituted heterocyclic aza derivatives.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
PH12018502139A1 (en) Phosphaplatin liquid formulations
UA110910C2 (en) Karboksamidni pyrazole derivatives as bruton tyrosine kinase inhibitors, pharmaceutical composition on the basis and method of treatment (options)
EA201500446A1 (en) PHARMACEUTICAL COMPOSITION TO REDUCE N-OXIDE TRIMETYLAMINE LEVEL
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
MX369393B (en) Phthalazine derivatives.
GB2519470A (en) Bicyclic aza compounds as muscarinic M1 receptor agonists
MX2015015845A (en) Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof.